Table 2.
Demographic, clinical, and standard cerebrospinal fluid in followed-up relapsing–remitting MS (RRMS).
| RRMS-1αlow N = 9 | RRMS-1αmedium N = 15 | RRMS-1αhigh N = 15 | p-value | |
|---|---|---|---|---|
| Gender (Female) | 7 (77.8%) | 10 (66.7%) | 11 (73.3%) | 0.83 |
| Age (y) | 31.11 ± 9.66 | 34.93 ± 8.29 | 37.07 ± 8.47 | 0.28 |
| Disease duration (m) | 10.00 ± 22.56 | 9.40 ± 10.78 | 12.20 ± 17.65 | 0.89 |
| ARR | 1.00 ± 0.50 | 0.93 ± 0.46 | 1.40 ± 0.63 | 0.06 |
| EDSS | 1.5 (1.0–4.0) | 1.5 (1.0–4.0) | 2.0 (1.0–5.0) | 0.92 |
| IgGOB | 6 (66.7%) | 11 (73.3%) | 14 (93.3%) | 0.22 |
| IgGIndex | 0.59 ± 0.14 | 0.76 ± 0.35 | 0.73 ± 0.21 | 0.27 |
| BBB | 2 (22.2%) | 3 (20.0%) | 3 (20.0%) | 0.99 |
| Treatments | 0.73# | |||
| None | 1 (11.1%) | 2 (13.3%) | 0 (0%) | − |
| Total first line | 7 (77.8%) | 10 (66.7%) | 14 (93.3%) | 0.34# |
| Glatiramer acetate | 0 (0%) | 5 (33.3%) | 2 (13.3%) | - |
| Teriflunomide | 0 (0%) | 1 (6.7%) | 3 (20.0%) | - |
| Dimethyl-Fumarate | 3 (33.3%) | 2 (13.3%) | 6 (40.0%) | - |
| Interferon | 4 (44.4%) | 2 (13.3%) | 3 (20.0%) | - |
| Total Second Line | 1 (11.1%) | 3 (20.0%) | 1 (6.7%) | 0.91# |
| Natalizumab | 1 (11.1%) | 2 (13.3%) | 0 (0%) | |
| Alemtuzumab | 0 (0%) | 1 (6.7%) | 1 (6.7%) | - |
Considering the discrepancy between these cut-offs, MS patients were divided in RRMS-1αlow (<0.495 pg/ml, nine patients), RRMS-1αmedium (0.495–0.736 pg/ml, 15 patients), and RRMS-1αhigh (>0.736 pg/ml, 15 patients). ARR, annualized relapse rate; EDSS, Expanded Disability Status Scale. Other abbreviations as in Table 1. #: to perform chi square, all null values were set at 1. The drug are reported in italics, while the type (first or second line) not.